197 related articles for article (PubMed ID: 16709552)
1. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning.
Knegtering H; Boks M; Blijd C; Castelein S; van den Bosch RJ; Wiersma D
J Sex Marital Ther; 2006; 32(4):315-26. PubMed ID: 16709552
[TBL] [Abstract][Full Text] [Related]
2. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning.
Knegtering R; Castelein S; Bous H; Van Der Linde J; Bruggeman R; Kluiter H; van den Bosch RJ
J Clin Psychopharmacol; 2004 Feb; 24(1):56-61. PubMed ID: 14709948
[TBL] [Abstract][Full Text] [Related]
3. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
Byerly MJ; Nakonezny PA; Bettcher BM; Carmody T; Fisher R; Rush AJ
Schizophr Res; 2006 Sep; 86(1-3):244-50. PubMed ID: 16730951
[TBL] [Abstract][Full Text] [Related]
4. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
5. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
Kim KS; Pae CU; Chae JH; Bahk WM; Jun TY; Kim DJ; Dickson RA
J Clin Psychiatry; 2002 May; 63(5):408-13. PubMed ID: 12019665
[TBL] [Abstract][Full Text] [Related]
6. Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.
Ahl J; Kinon BJ; Liu-Seifert H
Ann N Y Acad Sci; 2004 Dec; 1032():289-90. PubMed ID: 15677431
[TBL] [Abstract][Full Text] [Related]
7. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.
Konarzewska B; Wołczyński S; Szulc A; Galińska B; Popławska R; Waszkiewicz N
Psychoneuroendocrinology; 2009 Jan; 34(1):129-39. PubMed ID: 18838228
[TBL] [Abstract][Full Text] [Related]
8. Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone.
van Bruggen M; van Amelsvoort T; Wouters L; Dingemans P; de Haan L; Linszen D
Psychoneuroendocrinology; 2009 Aug; 34(7):989-95. PubMed ID: 19264412
[TBL] [Abstract][Full Text] [Related]
9. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone.
Westheide J; Cvetanovska G; Albrecht C; Bliesener N; Cooper-Mahkorn D; Creutz C; Hornung WP; Klingmüller D; Lemke MR; Maier W; Schubert M; Sträter B; Kühn KU
J Sex Med; 2008 Dec; 5(12):2816-26. PubMed ID: 18466271
[TBL] [Abstract][Full Text] [Related]
10. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.
Kinon BJ; Ahl J; Liu-Seifert H; Maguire GA
Psychoneuroendocrinology; 2006 Jun; 31(5):577-88. PubMed ID: 16488084
[TBL] [Abstract][Full Text] [Related]
11. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
Byerly MJ; Nakonezny PA; Rush AJ
Psychiatry Res; 2008 May; 159(1-2):115-20. PubMed ID: 18295343
[TBL] [Abstract][Full Text] [Related]
12. [Safety and tolerability of olanzapine versus risperidone: a one-year randomized study in outpatients with schizophrenia with prominent negative symptoms].
Ciudad A; Alvarez E; Bousoño M; Olivares JM; Gómez JC
Actas Esp Psiquiatr; 2007; 35(2):105-14. PubMed ID: 17401781
[TBL] [Abstract][Full Text] [Related]
13. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.
Jeong HG; Lee MS; Lee HY; Ko YH; Han C; Joe SH
Int Clin Psychopharmacol; 2012 Jul; 27(4):177-83. PubMed ID: 22407277
[TBL] [Abstract][Full Text] [Related]
14. [Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone].
Haefliger T; Bonsack C
Encephale; 2006; 32(1 Pt 1):97-105. PubMed ID: 16633296
[TBL] [Abstract][Full Text] [Related]
15. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
Montalvo I; Ortega L; López X; Solé M; Monseny R; Franch J; Vilella E; Labad J
Int Clin Psychopharmacol; 2013 Jan; 28(1):46-9. PubMed ID: 23232756
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
17. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine.
Nakonezny PA; Byerly MJ; Rush AJ
J Sex Marital Ther; 2007; 33(3):203-16. PubMed ID: 17454518
[TBL] [Abstract][Full Text] [Related]
18. Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis.
Pérez-Iglesias R; Mata I; Martínez-García O; Garcia-Unzueta MT; Amado JA; Valdizán EM; Vázquez-Barquero JL; Crespo-Facorro B
J Clin Psychopharmacol; 2012 Dec; 32(6):804-8. PubMed ID: 23131886
[TBL] [Abstract][Full Text] [Related]
19. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics.
Montejo AL; Majadas S; Rico-Villademoros F; Llorca G; De La Gándara J; Franco M; Martín-Carrasco M; Aguera L; Prieto N;
J Sex Med; 2010 Oct; 7(10):3404-13. PubMed ID: 20214720
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
